ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma
Male
Clinicopathology of Fibrous Tumors and Treatment Strategies
DNA Mutational Analysis
Adenoid Cystic -- genetics -- pathology
mutation ; spiradenoma ; spiradenocarcinoma
Gene
Whole Exome Sequencing
DNA Methyltransferase 3A
Cohort Studies
Somatic cell
Loss of Function Mutation
Cylindromatosis Gene
Germline mutation
80 and over
Pathology
Missense mutation
Adenoid Cystic
DNA (Cytosine-5-)-Methyltransferases
Aged, 80 and over
0303 health sciences
Q
Life Sciences
Middle Aged
Carcinoma, Adenoid Cystic
Deubiquitinating Enzyme CYLD
3. Good health
Technologie de l'environnement, contrôle de la pollution
Malignant transformation
Hedgehog Signaling in Development and Cancer
Medicine
Female
Protein Kinases -- genetics
Adult
572
Germline
Tumor Suppressor Protein p53 -- genetics
Science
Cylindroma
Mutation, Missense
610
Dermatology
Cancer research
Article
Protein Domains -- genetics
03 medical and health sciences
Protein Domains
Rheumatology
Deubiquitinating Enzyme CYLD -- genetics
Biochemistry, Genetics and Molecular Biology
Health Sciences
Adnexal Neoplasms
Genetics
Chimie
Humans
Cutaneous Adnexal Neoplasms and Related Syndromes
Sweat Glands -- pathology
Molecular Biology
Biology
Aged
Carcinoma, Adenoid Cystic -- genetics -- pathology
Physique
DNA (Cytosine-5-)-Methyltransferases -- genetics
Carcinoma
Astronomie
Sweat Gland Neoplasms -- genetics -- pathology
Sweat Glands
Sweat Gland Neoplasms
FOS: Biological sciences
Mutation
contrôle de la pollution
Technologie de l'environnement
Missense
Tumor Suppressor Protein p53
Protein Kinases
DOI:
10.1038/s41467-019-09979-0
Publication Date:
2019-05-17T10:04:09Z
AUTHORS (26)
ABSTRACT
AbstractSpiradenoma and cylindroma are distinctive skin adnexal tumors with sweat gland differentiation and potential for malignant transformation and aggressive behaviour. We present the genomic analysis of 75 samples from 57 representative patients including 15 cylindromas, 17 spiradenomas, 2 cylindroma–spiradenoma hybrid tumors, and 24 low- and high-grade spiradenocarcinoma cases, together with morphologically benign precursor regions of these cancers. We reveal somatic or germline alterations of the CYLD gene in 15/15 cylindromas and 5/17 spiradenomas, yet only 2/24 spiradenocarcinomas. Notably, we find a recurrent missense mutation in the kinase domain of the ALPK1 gene in spiradenomas and spiradenocarcinomas, which is mutually exclusive from mutation of CYLD and can activate the NF-κB pathway in reporter assays. In addition, we show that high-grade spiradenocarcinomas carry loss-of-function TP53 mutations, while cylindromas may have disruptive mutations in DNMT3A. Thus, we reveal the genomic landscape of adnexal tumors and therapeutic targets.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (57)
CITATIONS (58)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....